National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 11/06/2008



Purpose of This PDQ Summary






Overview






Etiopathogenesis






Oral and Dental Management Prior to Cancer Therapy






Management Following Cancer Therapy






Oral Mucositis






Infection






Hemorrhage






Neurotoxicity






Graft-versus-Host Disease






Posttransplantation Dental Treatment






Relapse and Second Malignancy






Oral Toxicities Not Related to Chemotherapy or Radiation Therapy






Head/Neck Radiation Patients






Conditions Affected By Both Chemotherapy and Head/Neck Radiation






Psychosocial Issues






Special Considerations in Pediatric Populations






Get More Information From NCI






Changes to This Summary (11/06/2008)






Questions or Comments About This Summary






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Relapse and Second Malignancy

Gingival infiltrates, oral infection, and/or bleeding disproportionate to local etiology can indicate possible relapsed disease. Painless unilateral lymphadenopathy can also represent relapse in patients with previously treated lymphoma.

Incidence of second malignancy can increase as cancer patients live longer. Previous exposure to chemotherapy and radiation and alterations in immune function, graft-versus-host disease (GVHD), and GVHD therapy collectively contribute to risk for second malignancy. Oral squamous cell carcinoma is the most frequently occurring secondary oral malignancy in transplant patients, with the lips and tongue being the most frequently reported sites.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov